Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By End User, By Region & Competition, 2021-2031F

Description

The Global Malignant Mesothelioma Therapeutics Market is projected to expand from USD 260.62 Million in 2025 to USD 382.21 Million by 2031, registering a compound annual growth rate of 6.59%. This market encompasses specialized pharmacological treatments, such as chemotherapy, immunotherapy, and targeted agents, designed to combat aggressive malignancies arising in the mesothelial linings of the heart, abdomen, or lungs. Market growth is primarily driven by the increasing implementation of regulatory-approved dual immunotherapy protocols and the enduring prevalence of asbestos-related cases in areas with a history of industrial exposure, representing structural demand rather than temporary prescription trends.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 260.62 Million
Market Size 2031	USD 382.21 Million
CAGR 2026-2031	6.59%
Fastest Growing Segment	Oral
Largest Market	North America

A significant obstacle hindering market growth is the difficulty in recouping substantial research and development expenditures given the condition's extreme rarity. The American Cancer Society reports that in 2025, the United States will see approximately 3,000 new mesothelioma diagnoses annually. This small patient base constrains the commercial potential of new treatments and makes recruiting adequate numbers of participants for late-stage clinical trials challenging, ultimately retarding the speed of therapeutic advancement.

Market Driver

The Global Malignant Mesothelioma Therapeutics Market is being fundamentally reshaped by rapid progress in immunotherapy and the authorization of innovative drug combinations. Pharmaceutical companies are successfully advancing beyond conventional chemotherapy-only regimens by deploying immune checkpoint inhibitors that offer improved survival outcomes for unresectable disease. This transition is highlighted by the U.S. Food and Drug Administration's September 2024 press release regarding the approval of pembrolizumab combined with chemotherapy for advanced or metastatic malignant pleural mesothelioma; this decision was supported by efficacy data indicating a 21% reduction in the risk of death compared to chemotherapy alone, a milestone that validates new mechanisms and compels the adoption of premium biologics.

Continued market demand is anchored by the long latency period of the disease and the legacy of extensive asbestos exposure, which maintains stable patient numbers in industrialized nations despite current bans. This persistent incidence ensures a steady population requiring treatment, as evidenced by the Health and Safety Executive's 'Mesothelioma Statistics for Great Britain, 2024' report from August 2024, which recorded 2,257 mesothelioma deaths in 2022. Such consistent prevalence sustains revenue for specialized companies, as reflected in Novocure's 2024 financial report showing third-quarter net revenues of $155.1 million, largely attributed to the uptake of its proprietary therapy in key markets.

Market Challenge

The scarcity of malignant mesothelioma presents a major economic obstacle that directly constrains the expansion of the global therapeutics sector. Manufacturers incur immense research and development expenses to create specialized therapies, yet the restricted global patient population provides a limited commercial path for recouping these heavy investments. This imbalance between high capital requirements and low potential sales volumes disincentivizes companies from prioritizing mesothelioma projects, resulting in a diminished pipeline of new drug candidates and fewer market participants compared to more common cancer indications.

Additionally, the rarity of patients imposes significant logistical challenges on the conduct of essential clinical trials. Obtaining a sufficient number of eligible subjects for large-scale studies is arduous, frequently causing prolonged enrollment phases and delays in regulatory filings. For instance, the Australian Institute of Health and Welfare noted in 2024 that only 684 new mesothelioma cases were diagnosed in Australia, illustrating how low incidence rates in major markets fragment the available trial population, thereby extending development timelines and retarding the entry of innovative therapies into the market.

Market Trends

The development of small molecule inhibitors targeting the Hippo pathway is emerging as a precise therapeutic strategy, particularly for mesothelioma driven by NF2 mutations. These novel agents are engineered to obstruct the interaction between YAP/TAZ and TEAD proteins, effectively halting the transcriptional activity that powers cancer cell growth. According to an October 2025 article by Fierce Biotech regarding a midstage trial, the experimental TEAD inhibitor VT3989 achieved a median progression-free survival of 40 weeks in treatment-resistant patients, significantly surpassing the 15-week benchmark of standard salvage chemotherapy and offering a vital alternative to systemic treatments.

Concurrently, the rise of mesothelin-targeted therapies is transforming the field, with a renewed emphasis on cellular interventions directing the immune system toward this surface protein. Developers are increasingly combining chimeric antigen receptor (CAR) T-cell therapies with checkpoint inhibitors to tackle the immunosuppressive tumor microenvironment typical of pleural malignancies. A report from Mesothelioma.com in August 2025 highlighted a recent study where mesothelin-targeted CAR T-cell therapy combined with pembrolizumab resulted in a median overall survival of 23.9 months, underscoring the potential of this multimodal approach to exceed historical second-line treatment outcomes.

Key Market Players

F. Hoffmann-La Roche Ltd
Novartis AG
Merck & Co. Inc.
Pfizer Inc.
Eli Lilly and Co.
Sanofi S.A.
AstraZeneca Plc
Bayer AG
Regeneron Pharmaceuticals Inc.
GSK Plc

Report Scope

In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malignant Mesothelioma Therapeutics Market, By Drug Type

Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Others

Malignant Mesothelioma Therapeutics Market, By Route of Administration

Oral
Parenteral

Malignant Mesothelioma Therapeutics Market, By End User

Hospitals
Cancer Centers
Others

Malignant Mesothelioma Therapeutics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malignant Mesothelioma Therapeutics Market.

Available Customizations:

Global Malignant Mesothelioma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malignant Mesothelioma Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral)
- 5.2.3. By End User (Hospitals, Cancer Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Malignant Mesothelioma Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By End User

7. Europe Malignant Mesothelioma Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By End User
- 7.3.2. France Malignant Mesothelioma Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Malignant Mesothelioma Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By End User

8. Asia Pacific Malignant Mesothelioma Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By End User
- 8.3.2. India Malignant Mesothelioma Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Malignant Mesothelioma Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Malignant Mesothelioma Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By End User

9. Middle East & Africa Malignant Mesothelioma Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By End User
- 9.3.2. UAE Malignant Mesothelioma Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By End User
- 9.3.3. South Africa Malignant Mesothelioma Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By End User

10. South America Malignant Mesothelioma Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By End User
- 10.3.2. Colombia Malignant Mesothelioma Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By End User
- 10.3.3. Argentina Malignant Mesothelioma Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Malignant Mesothelioma Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Merck & Co. Inc.
15.4. Pfizer Inc.
15.5. Eli Lilly and Co.
15.6. Sanofi S.A.
15.7. AstraZeneca Plc
15.8. Bayer AG
15.9. Regeneron Pharmaceuticals Inc.
15.10. GSK Plc